a place fir glp.1 and eating disprders 504: Adult Disorders in the GLP-1 Era Eating Disorder Treatment Centers -

In contrast, first-time prescribing of AOM semaglutide, which had been declining (~0.004 points/month), rose by +4.9% from June to July 2025its strongest monthly increase in over a year

Conclusion While we have a good understanding of the consequences of micronutrient deficiencies on cognition, we know considerably less about the cognitive effects of micronutrient supplementation

[19][20] BCBS (Massachusetts): Mounjaro is Step 2 therapy

In our study, serum GDF15 levels were significantly elevated in FM patients compared to healthy controls, suggesting its potential as a complementary biomarker for FM diagnosis and severity assessment

The goal is informed choice

In addition, GLP-1 drugs work on the brain to suppress appetite, says Dr